Galderma Group (GALD.SW)

Executive Summary

Galderma Group is a global pure-play dermatology company with a comprehensive portfolio spanning prescription, aesthetic, and consumer skincare segments. The company's prescription business addresses conditions like acne, rosacea, psoriasis, and skin cancer, while its aesthetic portfolio focuses on injectable products for facial contouring. With a direct presence in ~40 countries and a strong brand portfolio including Cetaphil and Restylane, Galderma has established itself as a leader in dermatology. The company completed its IPO on the SIX Swiss Exchange in March 2024, raising capital to support R&D and commercial expansion. In 2025, Galderma reported steady revenue growth driven by robust demand for its aesthetic injectables and prescription treatments, particularly in the U.S. and emerging markets. The company's pipeline includes several late-stage candidates targeting high-need dermatological conditions, positioning it for sustained growth. Management has guided for mid-single-digit organic sales growth in 2026, supported by new product launches and geographic expansion. Galderma's focus on innovation and its integrated business model provide a competitive edge in the attractive dermatology market, though it faces risks from regulatory changes and competition in aesthetics.

Upcoming Catalysts (preview)

• Q1 2026FDA approval decision for nemolizumab in prurigo nodularis80% success
• Q3 2026Launch of new Restylane filler in the U.S. market60% success
• Q3 2026Q2 2026 earnings release with potential guidance upgrade70% success